Loading…
OPKO Health, Inc. is projected to rise to $1.54 by 2027, a +16% move from its current price of $1.32. OPK is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $1.28 | $1.32 | $1.36 | +0.01% |
| Aug 3 | $1.26 | $1.32 | $1.38 | +0.02% |
| Aug 4 | $1.25 | $1.32 | $1.39 | +0.04% |
| Aug 5 | $1.24 | $1.32 | $1.40 | +0.05% |
| Aug 6 | $1.23 | $1.32 | $1.41 | +0.06% |
| Aug 7 | $1.23 | $1.32 | $1.42 | +0.07% |
| Aug 8 | $1.22 | $1.32 | $1.43 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.22 | $1.32 | $1.43 | +0.08% |
| Week 2 | $1.18 | $1.32 | $1.48 | +0.17% |
| Week 3 | $1.15 | $1.32 | $1.52 | +0.25% |
| Week 4 | $1.13 | $1.32 | $1.56 | +0.33% |
| Week 5 | $1.11 | $1.33 | $1.59 | +0.42% |
| Week 6 | $1.09 | $1.33 | $1.62 | +0.50% |
| Week 7 | $1.07 | $1.33 | $1.65 | +0.58% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
OPKO Health, Inc. operates as a healthcare company with activities in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics.
The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test.
OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
OPKO Health, Inc. is a healthcare company with a market presence in multiple countries and a diversified portfolio across Pharmaceutical and Diagnostics. The current price is $1.37 and the company has a market capitalization of $1.02B, with a rank of 2521.
The stock sits near the lower end of its technical range, and the long-term outlook shows meaningful upside in the published forecasts. The company’s price action and forecasts reflect a path of gradual expansion in value over time, with the 30-day technical picture and volatility shaping potential near-term risk and opportunity.
A major floor 31.8% below — a decisive break under it would weaken the trend.
The nearest floor, 11.4% below — buyers have tended to step in here.
The nearest ceiling, 25.0% above — a clean break opens room to run.
A major ceiling 40.9% above — clearing it would confirm fresh momentum.
Key OPK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OPK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.38 | Sell | $1.34 | Sell |
| MA 10 | $1.29 | Buy | $1.32 | Sell |
| MA 20 | $1.30 | Buy | $1.32 | Sell |
| MA 50 | $1.38 | Sell | $1.33 | Sell |
| MA 100 | $1.27 | Buy | $1.31 | Buy |
| MA 200 | $1.29 | Buy | $1.31 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.40 | Neutral |
| Stoch RSI (14) | 49.49 | Neutral |
| CCI (20) | 10.11 | Neutral |
| Williams %R (14) | -68.75 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 10.00 | Buy |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 31.25 | Neutral |
| TRIX (15) | -0.33 | Sell |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 55.72 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 1.44 | Sell |
| ADX (14) | 29.25 | Sell |
| ATR (14) | 0.06 | Info |
The 30-day range is $1.10 to $1.69, indicating a modestly wide near-term trading band. RSI14 stands at 50, with SMA50 equal to $1.37 and SMA200 at $1.29, suggesting a price that is tracking the short-term moving averages. Near-term support sits at $1.17 and resistance at $1.65, framing a shallow horizon for immediate moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.10 | $1.32 | $1.81 | 0% | Neutral | |
| $1.21 | $1.54 | $2.07 | +16% | Neutral | |
| $1.24 | $1.63 | $2.29 | +23% | Bullish | |
| $1.25 | $1.69 | $2.44 | +28% | Bullish | |
| $1.40 | $1.93 | $2.87 | +46% | Bullish | |
| $1.62 | $2.28 | $3.47 | +73% | Bullish | |
| $1.87 | $2.68 | $4.17 | +103% | Bullish | |
| $2.02 | $2.95 | $4.68 | +124% | Bullish | |
| $2.06 | $3.06 | $4.94 | +132% | Bullish | |
| $2.15 | $3.26 | $5.35 | +147% | Bullish | |
| $3.06 | $5.02 | $8.81 | +280% | Bullish | |
| $4.60 | $8.65 | $16.71 | +555% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.10 | $1.32 | $1.63 | +0.00% |
| September 2026 | $1.13 | $1.34 | $1.64 | +1.42% |
| October 2026 | $1.12 | $1.33 | $1.65 | -0.33% |
| November 2026 | $1.16 | $1.40 | $1.74 | +4.56% |
| December 2026 | $1.19 | $1.44 | $1.81 | +2.97% |
Click any year to see its month-by-month OPK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The OPK price prediction for 2026 points to an average of $1.32 (low $1.10, high $1.81) — a potential gain of 0% on today's $1.32. A consolidation phase looks the most probable path here.
In 2027, OPK is projected to trade between $1.21 and $2.07, averaging $1.54 — a potential gain of +16% from today's $1.32. That is up +16% on the projected 2026 average. Price action looks broadly range-bound.
OPKO Health, Inc.'s 2028 outlook centres on $1.63, within a $1.24 to $2.29 range. That is up +6% on the projected 2027 average. That marks a +23% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, OPK could reach as high as $2.44, with a base case around $1.69 and support toward $1.25 — roughly +28% from $1.32. Momentum favours further upside here.
Expect OPK to range from $1.40 to $2.87 through 2030. The $1.93 average target implies a +46% move from current prices. That is up +14% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The OPK price prediction for 2031 points to an average of $2.28 (low $1.62, high $3.47) — a potential gain of +73% on today's $1.32. Momentum favours further upside here.
In 2032, OPK is projected to trade between $1.87 and $4.17, averaging $2.68 — a potential gain of +103% from today's $1.32. That is up +18% on the projected 2031 average. Buyers look set to stay in control over this stretch.
OPKO Health, Inc.'s 2033 outlook centres on $2.95, within a $2.02 to $4.68 range. That is up +10% on the projected 2032 average. That marks a +124% change versus current levels. Momentum favours further upside here.
By 2034, OPK could reach as high as $4.94, with a base case around $3.06 and support toward $2.06 — roughly +132% from $1.32. Buyers look set to stay in control over this stretch.
Expect OPK to range from $2.15 to $5.35 through 2035. The $3.26 average target implies a +147% move from current prices. That is up +6% on the projected 2034 average. Momentum favours further upside here.
The OPK price prediction for 2040 points to an average of $5.02 (low $3.06, high $8.81) — a potential gain of +280% on today's $1.32. Buyers look set to stay in control over this stretch.
In 2050, OPK is projected to trade between $4.60 and $16.71, averaging $8.65 — a potential gain of +555% from today's $1.32. That is up +72% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in OPK today (≈ 757.575758 OPK) could be worth
$6,550.76
+$5,550.76 (+555%) by 2050 · US Dollar
Based on the average projected OPK price of $8.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OPKwould be worth at today's price.
$1,000 invested in OPK on Jul 31, 2025 (≈ 781.250017 OPK) would be worth
$1,031.25
+$31.25 (+3.1%) today · 1.03× · US Dollar
Based on a OPK entry price of $1.28 vs. today's $1.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.22 | $1,081.97 | +8.2% |
| 1 month ago | $1.53 | $862.75 | -13.7% |
| 3 months ago | $1.1 | $1,200 | +20.0% |
| 6 months ago | $1.28 | $1,031.25 | +3.1% |
| 1 year ago | $1.28 | $1,031.25 | +3.1% |
| All time (5.0y) ago | $3.55 | $371.83 | -62.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OPK forecast.
Our base-case forecast reaches $2.60 around 2032.
Implied market cap at $2.60: $1.94B
The multi-year forecast shows a rising trajectory for OPKO Health. The average price is projected to climb from $1.37 in 2026 to $2.02 in 2030, then higher to $5.40 by 2040 and $9.28 by 2050. The forecasted maximums follow a similar ascent, with $3.04 in 2030, $9.63 in 2040, and a peak of $18.31 in 2050.
The associated ROI figures rise from 0 in 2026 to 47.9 in 2030 and 580.2 by 2050, with sentiment described as bullish in the long horizon. The outlook displays a bullish trajectory across 2027 onward, underscored by higher average prices and expanding upside, but these are estimates and not guarantees. Investors should recognize the potential for volatility and the inherent uncertainty in long-range forecasts.
Tap a question to reveal the answer.
2030 forecast shows min $1.45, avg $2.02, max $3.04 with ROI 47.9 and sentiment bullish.
Long-term forecasts imply a strong upside, with avg price rising to $9.28 by 2050 and ROI 580.2%, and sentiment bullish in later years, though 2026 is neutral.
Yes—the 2035 forecast lists min $2.24, avg $3.46, max $5.75, indicating a potential path to $5 within the forecast horizon.
The current price is $1.37 and the market cap is $1.02B.
2031 shows min $1.70, avg $2.42, max $3.73 with ROI 77.1 and sentiment bullish.
OPKO Health, Inc. Community Discussion
0Share your OPKO Health, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.